Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

2016194 citationsJournal Articlehybrid Open Access

Authors

Patrick M. Moriarty · University of Kansas Medical Center

Klaus G. Parhofer

Stephan P. Babirak

Marc-Andre Cornier · University of Colorado Anschutz Medical Campus

P. Barton Duell · Oregon Health & Science University

Bernd Hohenstein · University Hospital Carl Gustav Carus

Josef Leebmann

Wolfgang Ramlow

Volker Schettler

Abstract

Lipoprotein apheresis was discontinued in 63.4% of patients on alirocumab who were previously undergoing regular apheresis, and the rate was at least halved in 92.7% of patients. Alirocumab was generally safe and well tolerated.

Topics & Keywords

Lipoproteins and Cardiovascular Health Pharmaceutical Economics and Policy Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 37, Issue 48, pp. 3588-3595

DOI: 10.1093/eurheartj/ehw388

Field-Weighted Citation Impact: 34.52